Judith L Treadway

6448263, Sep 10, 2002

Aug 26, 1999

09/380186

Philip Albert Carpino - Groton CT
Charles Kwok-Fung Chiu - Guilford CT
Lydia Codetta Pan - Mystic CT
Bruce Allen Lefker - Gales Ferry CT
Judith Lee Treadway - Mystic CT
Michael Paul Zawistoski - West Warwick RI

Pfizer Inc. - New York NY

A61K 31424

514303, 514341, 514403, 514405, 5483605, 5483601, 5483561, 5483631, 5483641, 5483661, 546245, 5463754

This invention is directed to methods of treating insulin resistance in a mammal which comprise administering an effective amount of a compound of formula I, where the variables are defined in the specification, or the stereoisomeric mixtures, diastereomerically enriched, diastereomerically pure, enantiomerically enriched or enantiomerically pure isomers, or the pharmaceutically acceptable salts and prodrugs thereof to said mammal. The compounds of formula I are growth hormone secretagogues and as such are useful for increasing the level of endogenous growth hormone. In another aspect this invention provides certain intermediates which are useful in the synthesis of the foregoing compounds and certain processes useful for the synthesis of said intermediates and the compounds of formula I. This invention is further directed to methods comprising administering to a human or other animal a combination of a functional somatostatin antagonist such as an alpha-2 adrenergic agonist and a compound of formula I.

6555569, Apr 29, 2003

Feb 16, 2001

09/785146

Joyce A. Sutcliffe - Clinton CT
Judith Lee Treadway - Mystic CT

Pfizer Inc. - New York NY

A61K 31405

514415, 514419, 514311, 514314, 514315, 514317, 514326, 514330, 51421019, 5142102

A pharmaceutical composition containing a glycogen phosphorylase inhibitor of Formula I or IA as defined herein is administered to a mammal to treat infection.

6630487, Oct 7, 2003

May 29, 2002

10/158649

Philip Albert Carpino - Groton CT
Charles Kwok-Fung Chiu - Guilford CT
Lydia Codetta Pan - Mystic CT
Bruce Allen Lefker - Gales Ferry CT
Judith Lee Treadway - Mystic CT
Michael Paul Zawistoski - West Warwick RI

Pfizer Inc. - New York NY

A61K 31435

514303, 514 19, 514403, 514405, 546118, 546119, 546120, 5483605, 5483601, 5483631, 5483641, 5483661

This invention is directed to methods of treating insulin resistance in a mammal which comprise administering an effective amount of a compound of formula I, where the variables are defined in the specification, or the stereoisomeric mixtures, diastereomerically enriched, diastereomerically pure, enantiomerically enriched or enantiomerically pure isomers, or the pharmaceutically acceptable salts and prodrugs thereof to said mammal. The compounds of formula I are growth hormone secretagogues and as such are useful for increasing the level of endogenous growth hormone. In another aspect this invention provides certain intermediates which are useful in the synthesis of the foregoing compounds and certain processes useful for the synthesis of said intermediates and the compounds of formula I. This invention is further directed to methods comprising administering to a human or other animal a combination of a functional somatostatin antagonist such as an alpha-2 adrenergic agonist and a compound of formula I.

6649634, Nov 18, 2003

Jun 14, 2001

09/881136

Dennis J. Hoover - Stonington CT
Bernard Hulin - Essex CT
William H. Martin - Essex CT
Judith L. Treadway - Gales Ferry CT

Pfizer, Inc. - New York NY

A61K 3144

514339, 5462774, 5462791

This invention relates to certain indole-2-carboxamides of formula (I) and the pharmaceutically acceptable salts and prodrugs thereof, wherein R is carboxy, (C -C )alkoxycarbonyl, C(O)NR R or C(O)R , useful as inhibitors of glycogen phosphorylase, methods of treating glycogen phosphorylase dependent diseases or conditions with such compounds and pharmaceutical compositions comprising such compounds.

6846820, Jan 25, 2005

Jun 17, 2003

10/464728

Dennis J. Hoover - Stonington CT, US
Bernard Hulin - Essex CT, US
William H. Martin - Essex CT, US
Judith L. Treadway - Gales Ferry CT, US

Pfizer Inc. - New York NY

C07D23702
A61K 3150

514247, 51425409, 544224, 544335, 544373

P-0000100001.

6867184, Mar 15, 2005

Jan 23, 2001

09/767633

Judith L. Treadway - Mystic CT, US

Pfizer, Inc. - New York NY

A61K038/28

514 4, 51425214, 514253, 514323, 514330, 514 18, 514415, 540295

The present invention provides methods of treating diabetic cardiomyopathy, the methods comprising administering to a patient having or at risk of having diabetic cardiomyopathy a therapeutically effective amount of a glycogen phosphorylase inhibitor. The present invention also provides methods of treating diabetic cardiomyopathy, the methods comprising administering to a patient having 1) diabetes and 2) having cardiovascular disease, ischemic heart disease, congestive heart failure, congestive heart failure but not having coronary arteriosclerosis, hypertension, diastolic blood pressure abnormalities, microvascular diabetic complications, abnormal left ventricular function, myocardial fibrosis, abnormal cardiac function, pulmonary congestion, small vessel disease, small vessel disease without atherosclerotic cardiovascular disease or luminal narrowing, coagulopathy, cardiac contusion, or having had or at risk of having a myocardial infarction a therapeutically effective amount of a glycogen phosphorylase inhibitor.

6867202, Mar 15, 2005

Jul 22, 2003

10/626198

Philip Albert Carpino - Groton CT, US
Charles Kwok-Fung Chiu - Guilford CT, US
Lydia Codetta Pan - Mystic CT, US
Bruce Allen Lefker - Gales Ferry CT, US
Judith Lee Treadway - Mystic CT, US
Michael Paul Zawistoski - West Warwick RI, US

Pfizer Inc. - New York NY

A61K031/33
A61K031/435
A61K031/415
C07D471/04
C07D231/54

514183, 514303, 514 19, 514403, 514405, 546118, 546119, 546120, 5483605, 5483601, 5483631, 5483641, 5483661

This invention is directed to methods of treating insulin resistance in a mammal which comprise administering an effective amount of a compound of formula I, where the variables are defined in the specification, or the stereoisomeric mixtures, diastereomerically enriched, diastereomerically pure, enantiomerically enriched or enantiomerically pure isomers, or the pharmaceutically acceptable salts and prodrugs thereof to said mammal. The compounds of formula I are growth hormone secretagogues and as such are useful for increasing the level of endogenous growth hormone. In another aspect this invention provides certain intermediates which are useful in the synthesis of the foregoing compounds and certain processes useful for the synthesis of said intermediates and th compounds of formula I. This invention is further directed to methods comprising administering to a human or other animal a combination of a functional somatostatin antagonist such as an alpha-2 adrenergic agonist and a compound of formula I.

20030004162, Jan 2, 2003

Mar 20, 2001

09/813335

Judith Treadway - Mystic CT, US

A61K031/541
A61K031/546
A61K031/427
A61K031/404

514/228200, 514/233500, 514/254090, 514/365000, 514/415000

The invention provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof an effective amount of a glycogen phosphorylase inhibitor; effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent. The invention further provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof a pharmaceutical composition comprising effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent.